B
Bull
Bull · 25%ATHA
$0.44
Scenario price
$6.750
-0.413 (-6.12%)At close
Loading chart…
- High
- 7.350
- Open
- 7.300
- VWAP
- 6.91
- Vol
- 70.31K
- Mkt Cap
- 101.19M
- Low
- 6.620
- Amount
- 485.63K
- EV/EBITDA, TTM
- 0.00
LeonaBio, Inc., formerly Athira Pharma, Inc., is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The Company's lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. ATH-1105 is a novel, orally available, brain-penetrant, next-generation small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease. Lasofoxifene is a novel, nonsteroidal SERM with a binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations.
Valuation Metrics
The current forward P/E ratio for LeonaBio Inc (ATHA) is -1.30, compared to its 5-year average forward P/E of -1.40.
Alphio AI Price Scenarios for ATHA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
8.505-15Yahoo FinanceAthena Gold Provides Exploration Update on Laird Lake Project
6.002-19CNBCLatest Rating Changes on Wall Street
1.001-19Yahoo FinanceAthena Gold Invites Investors to Vancouver Resource Investment Conference
3.501-09GlobenewswireAthira Pharma Rebrands to LeonaBio, Secures $90 Million Financing
9.012-20NASDAQ.COMWeekly Update: CYTK Receives Initial FDA Approval, INSM Concludes Rhinosinusitis Research, XOMA Purchases GBIO
ATHA FAQ — answered by Alphio AI
LeonaBio, Inc., formerly Athira Pharma, Inc., is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The Company's lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. ATH-1105 is a novel, orally available, brain-penetrant, next-generation small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease. Lasofoxifene is a novel, nonsteroidal SERM with a binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.